NCT02898506

Incretin-based Therapy in Late Preclinical Type 1 Diabetes

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: University of Oulu · Academic / Other
• Sex: All
• Age: 10 Years – 30 Years
• Healthy volunteers: Not accepted

Summary

The objective of the trial is to study whether daily treatment with liraglutide improves endogenous insulin secretion, postpones progression to overt Type 1 diabetes, and is tolerable and safe in subjects aged 10-30 years, who are positive for multiple islet autoantibodies and have dysglycemia.

Conditions

• Type 1 Diabetes

Interventions

Type	Name	Description
DRUG	Victoza®	Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
DRUG	Placebo	Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.

Timeline

• Start date: 2016-03-01
• Primary completion: 2021-06-01
• Completion: 2021-06-01
• First posted: 2016-09-13
• Last updated: 2022-01-25

Locations

4 sites across 2 countries: Finland, Sweden